AtriCure Inc provides atrial fibrillation solutions to medical centers. Its product lines for cardiac tissue ablation include Radio Frequency Ablation Devices and the cryoICE Cryoablation System. The primary product line for left atrial appendage management is the AtriClip System, which excludes the left atrial appendage by clamping the appendage from the outside, prevents blood flow between the left atrial appendage and the atrium, and avoids contact with circulating blood. Virtually all of the firm’s revenue is derived from sales of open-heart ablation, minimimally invasive ablation, and AtriClip products. AtriCure generates the majority of its revenue in the United States.